EGFR and non-small cell lung carcinoma: For EGFR, T790M is a standard-of-care biomarker predictive of resistance to erlotinib, gefitinib, and afatinib in NSCLC, D761Y is also considered a biomarker of resistance to gefitinib but this is less well evidenced (Table 2 and Supplementary Figure 12).